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One sentence summary: Adipose tissue-secreted WNT5A triggers vascular disease in obesity 
by activating migration of vascular smooth muscle cells, via a USP17/Rac1/NADPH oxidases-
dependent mechanism. 
 






Obesity is associated with changes in the secretome of adipose tissue (AT), which affects the 
vasculature through endocrine and paracrine mechanisms. Wingless-related integration site 
5A(WNT5A) and secreted frizzled related protein 5 (SFRP5), adipokines that regulate non-
canonical Wnt signaling, are dysregulated in obesity. We hypothesised that WNT5A released 
from AT exerts endocrine and paracrine effects on the arterial wall through non-canonical  
RAC1-mediated Wnt signaling. In a cohort of 1,004 humans with atherosclerosis, obesity was 
associated with increased WNT5A bioavailability in the circulation and the AT, higher 
expression of WNT5A receptors Frizzled 2 and 5 in the human arterial wall, and increased 
vascular oxidative stress due to activation of NADPH oxidases. Plasma concentration of 
WNT5A was elevated in patients with coronary artery disease compared to matched controls 
and was independently associated with calcified coronary plaque progression. We further 
demonstrated that WNT5A induces arterial oxidative stress and redox-sensitive migration of 
vascular smooth muscle cells via Frizzled 2-mediated activation of a previously 
uncharacterised pathway involving the deubiquitinating enzyme ubiquitin-specific protease 17 
(USP17) and the GTPase RAC1. Our study identifies WNT5A and its downstream vascular 
signaling as a link between obesity and vascular disease pathogenesis, with translational 
implications in humans. 
 
Introduction 
Evidence suggests that obesity is closely related to vascular disease (1). However, the described 
U-shaped association between body mass index (BMI) and mortality(2) indicates the need for 
better understanding of the links between adipose tissue (AT) biology and vascular 
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(patho)physiology in order to develop therapeutic strategies to prevent the vascular 
complications of obesity. 
AT is a dynamic organ with regional biological variability (3), secreting a wide range of 
adipocytokines with vascular effects (4, 5). Perivascular AT (PVAT) exerts paracrine effects 
on the vascular wall, whereas “remote” AT depots such as subcutaneous (ScAT) and thoracic 
AT (ThAT) exert endocrine effects by enriching the circulating adipocytokine pool. Recent 
evidence suggests that obesity is associated with a shift of the AT secretome from 
vasoprotective/anti-atherogenic to a pro-atherogenic phenotype (6).  
Redox signaling is central to vascular disease, exerting multiple cytotoxic and pro-
inflammatory effects (7). NADPH oxidases ( NOX) are major sources of vascular reactive 
oxygen species (ROS), and the activity of some NOX isoforms (namely  NOX 1 and  NOX 2) 
is dependent on the GTPase RAC1(8). In turn, ROS regulate the migration of vascular smooth 
muscle cells (VSMCs) to the intima layer of the vascular wall, which is involved in vascular 
disease processes such as atherosclerotic plaque formation (9). However, the mechanisms by 
which obesity affects vascular redox signaling are unclear. 
The wingless-related integration site (Wnt ) signaling pathway is activated by a family of Wnt 
glycoprotein ligands consisting of 19 members in humans (10) and is negatively regulated by 
secreted frizzled related proteins (Sfrp), which act as decoy receptors for Wnt ligands (11). 
Downstream Wnt signaling is mediated by the canonical pathway, which involves β-catenin 
and is triggered by WNT3 (10), and the non-canonical pathways, which do not involve β-
catenin and are triggered by WNT5A and WNT11(12, 13). Despite the established role of non-
canonical Wnt signaling in cancer biology, its role in vascular disease pathogenesis in the 
context of obesity is unknown. 
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Recent work suggests that AT secretes WNT5A and SFRP5(14), molecules with potential 
vascular effects (15).  Imbalance in the AT production of WNT5A and SFRP5 in obesity may 
result in a ‘vicious cycle’ of increased AT inflammation and insulin resistance (14), indirectly 
triggering vascular complications of obesity. However, the potential role of AT-derived 
WNT5A and SFRP5as direct mediators of atherogenesis in obesity has not been investigated 
so far. We hypothesised that dysregulated AT secretion of WNT5A and SFRP5may lead to 
altered endocrine and paracrine effects on the vascular wall in obesity. We further explored the 




Wnt ligand expression profile in adipose tissue depots from patients with atherosclerosis 
We first explored the gene expression profile of all 19 Wnt ligands in human PVAT, ThAT 
and ScAT. WNT5A was the most highly expressed Wnt ligand in PVAT (Fig. 1A), whereas 
WNT11 was the most highly expressed Wnt ligand in ThAT and ScAT, with WNT5A still being 
among the four most highly expressed Wnt ligands in these depots ( Fig. 1, B and C). As both 
WNT5A and WNT11 are known to be non-canonical Wnt signaling pathway activators, and 
considering that WNT5A is the most abundant PVAT-derived paracrine ligand of the two, we 
focused on the potential role of WNT5A as a mediator of the vascular complications of obesity 
via non-canonical Wnt signaling. 
 
WNT5A and SFRP5adipose gene expression profiles in obesity 
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Plasma WNT5A was significantly increased in obese humans (Fig. 1D), accompanied by 
reduced plasma concentration of its antagonist SFRP5 (Figure 1E). We then focused on 
evaluating the WNT5A/SFRP5 ratio(16), since this is regarded as a more accurate integrated 
indication of overall Wnt signaling balance compared to evaluating WNT5A and 
SFRP5concentrations individually. We observed a strong positive correlation between BMI 
and plasma WNT5A/SFRP5 ratio (Figure 1F). Consistently, there was a positive association 
between BMI and the gene expression of WNT5A/SFRP5 in human ThAT (Fig. 1, G-I), but not 
in human ScAT (fig. S1, A-C). This suggests that increased WNT5A/SFRP5 gene expression 
in visceral adiposity (ThAT) could be linked with obesity-related vascular disease in humans. 
 
Interactions between obesity, WNT5A/SFRP5 and vascular disease 
We next explored the associations between obesity, WNT5A/SFRP5, and markers of vascular 
disease. Although obesity was not associated with the gene expression of WNT5A (Figure 2A), 
SFRP5 (Figure 2B), or the WNT5A/SFRP5 ratio in human IMAs (Figure 2C), it was linked 
with significantly altered gene expression of WNT5A and SFRP5in human PVAT. PVAT from 
obese/morbidly obese patients expressed significantly more WNT5A (Figure 2D), less SFRP5 
(Figure 2E), and thus had a higher WNT5A/SFRP5 ratio compared to lean counterparts (Figure 
2F). Obesity was related to a significant increase in the gene expression of WNT5A receptors 
Frizzled 2 (FZD2) (Figure 2G) and Frizzled 5 (FZD5) (Figure 2H) but not receptor tyrosine 
kinase-like orphan receptor 1 (ROR1) (Figure 2I) in human IMAs. This suggests that, in obese 
humans, arteries display increased sensitivity to the consequences of Wnt signaling, which may 
be a mechanistic link to the increase in arterial oxidative stress observed in obesity. 
To evaluate the association between the WNT5A/SFRP5 ratio and coronary artery disease 
(CAD) in humans, we designed a case-control study (study 2) in which 70 patients with CAD 
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were matched for age, gender, and BMI with 70 controls without obstructive CAD [confirmed 
by computed tomography (CT) angiography as having no coronary plaque causing>50% 
luminal stenosis]. Patients with CAD hadhigher plasma WNT5A (Figure 2J), lower SFRP5 
(Figure 2K), and a higher plasma WNT5A/SFRP5 ratio (Figure 2L) compared to controls. The 
presence of CAD was associated with circulating WNT5A (Bstand = 0.23, P = 0.00), SFRP5 
(Bstand = - 0.21, P = 0.00) and their ratio (Bstand = 0.21, P = 0.00) independently of traditional 
risk factors that differed significantly between the two cohorts of study 2 (Figure 2M). 
WNT5A/SFRP5 and all cardiovascular risk factors (hypertension, hyperlipidaemia, diabetes, 
and smoking) were associated with the presence of CAD by univariate analysis (table S1). 
However, in a multivariable model that included WNT5A/SFRP5 and all risk factors, only 
hypertension and hyperlipidaemia remained independently associated with CAD, 
independently from each other (Fig. 2M). 
To explore the potential value of WNT5A as a surrogate biomarker of vascular disease 
progression in humans, we designed a validation study (study 3) that involved individuals 
scanned by non-contrast CT at two different time points, 3-5 years apart, for evaluation of 
coronary calcified plaque burden. In 68 individuals studied, plasma WNT5A concentration was 
significantly elevated in patients that demonstrated calcified plaque progression, defined as a 
difference in coronary calcium score (CCS) ≥1 (n=32) (Figure 2N; baseline CCS: 0.00[0.00-
76.70] and follow-up CCS: 15.63[0.00-182.88] presented as median [25th-75th percentile ] in 
the entire study 3; differences in CCS between baseline and follow-up (ΔCSS) are further 
presented in Fig. 2N for each group)).  Similarly, in 38 patients with baseline CCS=0, plasma 
WNT5A was positively associated with the development of new calcification (follow-up CCS: 
0.00[0.00-6.93] presented as median [25th-75th percentile] in the entire study arm; follow-up 
CCS values in the new onset calcification group are also further presented in Fig. 2O). Upon 
multivariate regression analysis, plasma WNT5A was associated with progression of 
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calcification (Bstand=0.242, P=0.047) and new onset calcification (Bstand=0.367, P=0.03) 
independently of age and sex (table S3). 
 
WNT5A/SFRP5 as regulators of redox state in the human arterial wall 
We observed that BMI was not only associated with increased circulating and AT 
WNT5A/SFRP5 ratio but also with higher basal (Figure 3A) and NADPH-stimulated (Figure 
3B) superoxide (O2.-) generation in human internal mammary artery (IMA) segments. To 
examine whether the WNT5A/SFRP5 balance could alter human arterial redox state and thus 
be a mechanistic link between obesity and oxidative stress, we next explored the interactions 
between O2.- generation in human IMAs and WNT5A/SFRP5 ratio in plasma and PVAT from 
the patients in study 1. High plasma WNT5A/ SFRP5 ratio as well as high WNT5A/ SFRP5 
expression in PVAT were related with higher basal and NADPH-stimulated O2.- production in 
human IMAs (Figures 3C-F), whereas arterial WNT5A/SFRP5 gene expression was not 
associated with arterial redox state (Figure 3G-H). Since endogenous WNT5A gene expression 
in the human IMA is negligible compared to that in PVAT (fig. S1D), we hypothesised that the 
effects of WNT5A on the arterial wall are endocrine (resulting from its increased concentration  
in the circulation and reaching the endothelium and VSMCs via the lumen and vasa vasorum 
for large arteries) and paracrine (reaching the VSMCs and the endothelium via diffusion from 
the PVAT) rather than autocrine.  
To understand whether the association between obesity and NADPH oxidase activity in human 
arteries is dependent on the WNT5A/SFRP5 ratio in PVAT, we performed multivariate analysis 
in which arterial NADPH-stimulated O2.- was used as dependent variable, and obesity 
classification, diabetes, smoking, sex and age were used as independent variables. In the 
presence of WNT5A/SFRP5 gene expression in PVAT, in the model, obesity was not a 
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significant predictor of arterial NADPH-stimulated O2.-, suggesting that the effects of obesity 
on human arterial redox state are WNT5A-dependent  (table S4). 
To explore whether the associations between WNT5A/SFRP5 and human vascular redox state 
are causal, we used ex vivo models of human IMAs (study 4), whereby serial IMA rings were 
incubated with WNT5A (100 ng/ml), SFRP5 (300 ng/ml), or the combination of the two factors 
for 45 minutes, and O2.- generation was evaluated using lucigenin chemiluminescence and 
confirmed with dihydroethidium (DHE) staining. The concentration of WNT5A selected was 
near the maximum of the physiological levels of plasma WNT5A in patients of study 1 (range: 
1-112 ng/ml). WNT5A induced a 4-fold increase in arterial basal O2.-, an effect prevented by 
co-incubation with SFRP5 (Figure 3I). Similarly, NADPH-stimulated O2.- was increased (>2-
fold) by WNT5A incubation, an effect prevented by SFRP5 (Figure 3J), and the same was 
observed when measuring the signal inhibited by the pan-NOX inhibitor Vas2870 (Figure 3K).  
The specificity of the signal and the structural O2.- localization within the human arterial wall 
were examined using DHE staining of human IMAs. Incubation of human IMAs with WNT5A 
for 45 minutes increased O2.- generation, mainly from the VSMCs layer, an effect partially 
attenuated by SFRP5 and completely reversed by Vas2870 (Figure 3L), confirming that the 
effect was dependent upon NADPH oxidases. To examine whether the consequences of 
WNT5A on vascular redox state are dependent on the activation of NADPH oxidases, we 
explored its effects on vascular O2.- after pre-incubation of human arteries with Vas2870. In 
the presence of Vas2870, WNT5A failed to increase vascular O2.-, confirming the central role 
of NADPH oxidases on the  WNT5A -induced increase in vascular oxidative stress (Figure 
3M-N). However, WNT5A did not affect the expression of any of the NOX isoforms  (NOX1, 
NOX2, NOX4, or NOX5, fig. S2). In addition, plasma WNT5A/SFRP5 was not correlated with 
the expression of  NOX2, NOX4 or NOX5 (fig. S3). 
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WNT5A also reduced nitric oxide (NO) bioavailability in human vessels [evaluated by ex vivo 
vasorelaxation in response to Acetylcholine (ACh)], an effect reversed by SFRP5 (fig. S4).  
WNT5A had no effect on the endothelium-independent responses to the NO donor sodium 
nitroprusside (SNP). To understand the underlying mechanism, we explored the effect of 
WNT5A on endothelial nitric oxide synthase (eNOS) coupling. WNT5A induced eNOS 
uncoupling in human arteries, demonstrated by increased LNAME-inhibitable O2.- , an effect 
reversed by SFRP5 (fig. S4). WNT5A promoted eNOS uncoupling by inducing the oxidation 
of eNOS co-factor tetrahydrobiopterin (BH4) without affecting the biopterin biosynthetic 
pathway (no modification of total vascular biopterin content, fig. S4). These data identify 
WNT5A as a regulator of vascular redox state that induces global changes in vascular redox 
signaling, influencing both VSMCs and the endothelium. 
To further determine the causal effects of WNT5A on vascular NADPH oxidases activity in 
vivo, we used a doxycycline-inducible TetO mouse model (Wnt5a +/rtTA+ mice) to induce 
global overexpression of Wnt5a. Treatment of Wnt5a+/rtTA+ mice with doxycycline induced 
marked overexpression of  Wnt5a in multiple tissues (fig. S5) resulting in increased plasma 
WNT5A compared to doxycycline-treated Wnt5a–/rtTA+ littermate controls (Fig. 3O). 
Wnt5a+/rtTA+ mice demonstrated higher basal, NADPH-stimulated, and Vas2870-inhibitable 
aortic O2.- generation (Fig. 3P-R) compared to Wnt5a–/rtTA+ controls, confirming that in vivo 
overexpression of WNT5A leads to activation of arterial NADPH oxidases. 
 
Investigating the mechanism of  WNT5A -induced arterial NADPH oxidases activation, we 
found that WNT5A activated the non-canonical planar cell polarity (PCP) Wnt signaling 
pathway, documented by c-Jun N-terminal kinase (JNK) phosphorylation (an established 
surrogate marker of PCP activation) in human IMAs as well as in the aortas of Wnt5a+/rtTA+ 
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mice (Fig. 4, A and B, respectively). WNT5A induced RAC1activation (Figure 4C) in human 
arteries, leading to membrane translocation of RAC1and P47phox subunits of NADPH oxidases 
(Fig. 4D and E), which are crucial for the activation of the NOX1 and NOX2 isoforms of 
NADPH oxidases. The key role of RAC1 in the  WNT5A -mediated NADPH oxidases 
activation was shown by demonstrating that the specific RAC1inhibitor NSC23766 prevented 
the  WNT5A -induced increase of basal, NADPH-stimulated, and Vas2870-inhibitable O2.- in 
human IMAs (Figures 4F-H) and the aortas of Wnt5a+/rtTA+ mice (Fig. 4I-K). 
 
Adipocyte-derived WNT5A as a paracrine regulator of redox state in human VSMCs 
To explore whether adipocyte- derived WNT5A can exert paracrine effects that control the 
redox state in the neighboring VSMCs, we first confirmed that recombinant WNT5A activates 
the PCP pathway (JNK-phosphorylation) and activates RAC1in primary human VSMCs in 
culture (fig. S6, Fig. 5, A and B) similarly to intact vessels. We confirmed that a physiological 
concentration of WNT5A (100 ng/mL) did not activate the canonical Wnt signaling pathway 
(evaluated by quantifying active beta catenin), in contrast to supra-physiological WNT5A 
concentrations (400 ng/ml), which activated canonical Wnt signaling (Fig. 5C). Incubation 
with WNT5A (100 ng/mL) increased basal, NADPH-stimulated, and Vas2870-inhibitable O2.- 
in VSMCs (Fig. 5D-F), suggesting that the effects observed at the level of whole vessel are 
largely driven by direct effects of WNT5A on VSMCs. We next used immortalized primary 
human preadipocytes endogenously expressing and secreting WNT5A and knocked down 
WNT5A using shRNA (Fig. 5G). We observed a significant reduction in basal VSMC O2.- when 
VSMCs were co-cultured with  WNT5A -knockout (KO) adipocytes compared to sham control 
adipocytes (Fig. 5H). This reduction was due to a specific effect on the NOX2 isoform of 
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NADPH oxidase in VSMCs, as confirmed by significant reduction in gp91-dstat-inhibitable 
O2.- (gp91-dstat is a specific NOX2 inhibitor, Fig. 5I). 
To further understand how WNT5A exerts its effects on human VSMCs in obesity, we 
knocked-down FZD2 and FZD5 (two receptors upregulated in arteries of obese humans) in 
VSMCs using siRNA (Fig. 6A-C). Down-regulation of FZD2 was ~96%, and prevented the  
WNT5A -induced increase of basal, NADPH-stimulated, and Vas2870-inhibitable O2.- in 
human VSMCs (Fig. 6D-F). Knocking down FZD5 was less efficient in this model, with ~65% 
reduction of the gene expression in human VSMCs, and was related with a moderate reduction 
of the  WNT5A-induced increase of basal (Fig. 6G) but not NADPH-stimulated (Fig. 6H) or 
Vas2870-inhibitable (Fig. 6I) O2.-. 
 
Effects of WNT5A on human VSMC migration 
To better understand the cellular effects of WNT5A signaling on VSMC biology and the 
contribution of redox signaling in this context, we incubated human VSMCs with WNT5A 
(100 ng/ml) in the presence or absence of pegylated superoxide dismutase (peg-SOD, 100 
IU/mL), a scavenger of O2.-, and performed microarray analysis to evaluate the differential 
gene expression profile induced by WNT5A compared to non-treated controls. WNT5A altered 
the expression of 1,890 differentially expressed genes (DEGs), of which 1,057 genes were 
upregulated and 833 were down regulated (fig. S7A). 
The protein products of a substantial number of these DEGs were implicated in signal 
transduction pathways controlling cell growth, cell division, cell death, cell fate, and cell 
motility (fig. S6B). Functional annotation using Gene Ontology (GO) database showed that 
135 of these DEGs were involved in cell motility, acting through pathways known to regulate 
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cell migration (Fig. 7, A-B). Thus, we hypothesised that WNT5A could influence the migration 
of primary human VSMCs. 
We exposed human VSMCs to WNT5A (100 ng/ml) in the presence or absence of SFRP5 (300 
ng/ml) and investigated changes in the ability of these cells to migrate using wound healing 
(fig. S7, C-D) and Boyden chamber (Fig. 7C) assays. WNT5A increased the migration of 
human VSMCs in a  SFRP5-reversible manner (Fig. 7C-D), without affecting their 
proliferation (Fig. 7E). WNT5A could also induce a phenotypic switch of VSMCs, 
characterised by loss of contractile phenotype markers ACTA2 (actin α2, smooth muscle) and 
TGLN (trasngelin, or smooth muscle protein 22α, SM22α) and increased ratio of 
metalloproteinase 9 (MMP9) to MMP inhibitors TIMP1 and TIMP2 (fig. S8). 
 
Ubiquitin-specific protease 17 (USP17) as a downstream mediator of  WNT5A -mediated 
redox signaling 
To determine the contribution of redox signaling to WNT5A -induced VSMC migration, we 
incubated primary human VSMCs with WNT5A in the presence or absence of peg-SOD. Peg-
SOD prevented the  WNT5A -induced changes in VSMC migration (Fig. 8A), suggesting that 
the changes in intracellular redox state described previously at least partially mediate the pro-
migratory effects of WNT5A. Microarray results revealed that the effect of WNT5A on 28 of 
the previously described migration-related DEGs was reversed (at least partly) by peg-SOD, 
highlighting the DEGs as potential redox-sensitive genes (Fig. 8B). 
The maximally differentially regulated (upregulated) gene in response to WNT5A was USP17, 
a member of a deubiquitinating enzyme multigene family within a tandemly repeated sequence 
(17) (Figure 8B and fig. S9A). VSMCs isolated from 10 patients were subjected to in vitro 
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WNT5A treatment with or without peg-SOD, and quantitative real time polymerase chain 
reaction (q-RT-PCR) confirmed that WNT5A increases the expression of USP17  (Figure 8C). 
USP17 was previously found to be involved in the activation of small GTPases (18) and to 
regulate cell motility (fig. S6).  
To address the mechanistic role of USP17 in  WNT5A -mediated RAC1activation, we knocked 
down USP17 using shRNA in HeLa cells (fig. S9B) and treated these cells with WNT5A 
(100ng/mL). WNT5A failed to induce persistent RAC1activation in USP17-KO HeLa cells as 
opposed to empty vector control cells (Fig. 8D). These data support the role of USP17 as a 
mediator of  WNT5A -induced RAC1activation and  RAC1-mediated redox signaling, 
identifying a potential therapeutic target.  
 
Discussion 
We demonstrate that obesity leads to an imbalance between WNT5A and SFRP5expression in 
PVAT and other adipose tissue depots such as ThAT, as well as alterations in circulating 
plasma concentrations in human vascular disease. We show that obesity is associated with 
upregulation of WNT5A receptors Fzd2 and Fzd5, which are involved in non-canonical Wnt 
signaling in human arteries. WNT5A secreted by human adipocytes enhances arterial NADPH 
oxidases activity, increasing O2.- generation and inducing endothelial dysfunction and eNOS 
uncoupling. This O2.- excess (by both and NADPH oxidases and, secondarily, uncoupled 
eNOS) induces redox-driven migration in VSMCs via USP17/ RAC1 activation, which may 
explain the clinical association of WNT5A with vascular disease. Patients with high plasma 
WNT5A were at higher risk for calcified plaque progression and new-onset coronary 
calcification. This work identifies WNT5A, its balance with SFRP5, and its receptors and 
downstream signaling network as mechanistic links between obesity and vascular 
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complications in humans, and as a potential therapeutic target for the prevention and treatment 
of such complications. 
AT tissue biology displays remarkable regional variability and is dysregulated in obesity (19). 
Several studies have documented the biological discrepancy between visceral and superficial 
AT (20) and identified inflamed visceral AT as a source of adipocytokines with detrimental 
paracrine and endocrine effects on the vasculature (5). Previous studies have shown that 
WNT5A is expressed in the human adipose tissue (21), and have suggested that the balance 
between WNT5A and its decoy inhibitor SFRP5 may be involved in the pathogenesis of obesity 
and diabetes (21). We hypothesised that WNT5A and SFRP5 secretion from dysfunctional 
adipose tissue could play a role in the development of vascular disease in obesity.  
After observing that WNT5A was the most abundant Wnt ligand expressed in the human 
PVAT, we confirmed that obesity was associated high WNT5A and low SFRP5plasma 
concentrations in patients with CAD. We observed a similar shift of the WNT5A/SFRP5 gene 
expression ratio in ThAT and PVAT surrounding the IMA. It is therefore likely that increased 
WNT5A release from these visceral AT depots -- as well as the overall increased mass of these 
adipose tissue depots in obesity -- contributes to the obesity-related increase in plasma 
WNT5A.  Obesity not only increased the exposure of the human arteries to high circulating 
WNT5A/ low SFRP5 (inside-to-outside vascular effects, from the lumen to the vascular wall) 
and high  WNT5A / low SFRP5from PVAT (outside-to-inside vascular effects, from PVAT to 
the vascular wall), but it also led to upregulation of WNT5A receptors Fzd2 and Fzd5 in the 
human arterial wall. These receptors increased arterial sensitivity to non-canonical Wnt 
signaling. The combination of increased plasma WNT5A, together with the increased release 
of WNT5A from PVAT, drives the endocrine and paracrine effects, respectively, of adipose 
tissue-derived WNT5A on the human vascular wall. In a second nested case-control study, we 
showed a striking increase of plasma WNT5A accompanied by reduced circulating Sfpr5 in 
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patients with CAD compared to age, sex, and BMI matched non-CAD controls. Plasma 
WNT5A was positively and independently associated with both coronary calcification 
progression and new onset calcification in humans, suggesting that it has a clinically relevant 
role in vascular disease progression. 
Previous reports have suggested that WNT5A may be involved in endothelial dysfunction, 
particularly in the context of diabetes (22, 23). These studies elegantly supported the notion 
that WNT5A signaling has vascular implications; however, the ability of WNT5A to regulate 
vascular redox state was unclear. Considering that obese individuals have elevated vascular 
oxidative stress due to activation of NADPH oxidases, we hypothesised that AT-derived 
WNT5A is a link between dysfunctional AT and vascular disease in obesity, and this could be 
mediated by its effects on human arterial redox state. Redox signaling is directly involved in 
multiple vascular diseases commonly presented as complications of obesity (24-26). NADPH 
oxidases comprise major sources of ROS in the human vascular wall (8). The activation of 
NOX1 and NOX2 isoforms of NADPH oxidases is dependent on the activation and membrane 
translocation of RAC1and P47phox cytoplasmic subunits in order to form the active enzymatic 
complex (27). Given that non-canonical Wnt signaling has been linked with activation of small 
GTPases like Rac, we hypothesised that adipose tissue-derived WNT5A may drive arterial 
oxidative stress via  RAC1-mediated NADPH oxidases activation in obesity, as well as by 
eNOS uncoupling via BH4 oxidation.  
Here we demonstrated that high WNT5A/SFRP5 ratio, either in plasma or in PVAT 
surrounding human arteries, is related to significantly higher O2.- generation in these vessels. 
The causal association of WNT5A with human arterial O2.- was subsequently confirmed using 
ex vivo models of human arteries, and the precise mechanisms were further elucidated in vitro 
using primary human VSMCs. The in vivo effects of WNT5A on vascular NADPH oxidases 
activity was then confirmed using a doxycycline-inducible tet-O- WNT5A model. WNT5A 
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appears to trigger non-canonical Wnt signaling at low (physiological) concentrations, as 
confirmed in our work, whereas high, supra-physiological concentrations of WNT5A may 
trigger canonical Wnt signaling. The effect of physiological concentrations of WNT5A on 
cellular redox state in human VSMCs is mediated by Fzd2 receptor-induced non-canonical 
activation of RAC1, resulting in the translocation of GTP- RAC1 and P47phox to the cell 
membrane and leading to enzymatic stimulation of NADPH oxidases in the vasculature. Co-
culture of human adipocytes with human VSMCs revealed that knocking-down WNT5A in 
human pre-adipocytes results into a reduction of O2.- generation by NOX2in VSMCs, 
confirming the paracrine role of adipocyte-derived WNT5A on vascular redox state. 
The balance between VSMCs migration and proliferation versus apoptosis is crucial for the 
stability of atherosclerotic plaques (28). Migration of these cells is believed to contribute to 
atherogenesis, particularly at the early disease stage (29). VSMCs may undergo a phenotypic 
switch whereby they lose their contractile phenotype markers and start producing 
metalloproteinases which may lead to fibrous cap thinning a plaque rupture (28). Previous 
studies have linked WNT5A signaling to reduced VSMCs apoptosis (30), but this effect was 
attributed to canonical Wnt signaling achieved using a supra-physiological WNT5A 
concentration in vitro (30). Conversely, WNT5A stimulates cellular motility and migration via 
non-canonical signaling in a variety of cell types (31, 32), while oxidative stress can also 
promote the migration of VSMCs (9). In this context, we hypothesised that WNT5A may affect 
VSMC phenotype and specifically lead to VSMC migration at least partially via induction of 
redox signaling. 
We demonstrated that WNT5A induces migration of human VSMCs in a redox-sensitive 
manner which is reversed by peg-SOD, a scavenger of intracellular O2.-. WNT5A may cause a 
VSMC phenotypic switch, evidenced by downregulation of contractile gene markers ACTA2 
and TAGLN (28) and a concomitant increase in the bioavailability of MMP9, a 
17 
 
metalloproteinase with strong associations with plaque rupture (33). Transcriptome analysis 
revealed that WNT5A regulates a number of migration-related genes in human VSMCs, thus 
potentially exerting multiple effects on VSMC migration. USP17, a deubiquitinating enzyme 
acting as a known activator of small GTPases like RAC (18), was the top hit up-regulated by 
WNT5A (and partly reversed by peg-SOD) in VSMCs. The USP17/ RAC1 link has previously 
been implicated in diseases in which cell motility plays a pivotal role, such as tumorigenesis 
(34). However, USP17 has not previously been implicated in vascular biology, nor has it been 
proposed as a downstream target of WNT5A signaling. Our data supports a role for USP17 in 
mediating the effects of WNT5A on RAC1activation and controlling vascular redox state, 
while the link between WNT5A and USP17 also appears to be partly redox-sensitive.  These 
data identify the WNT5A/USP17/RAC1/NADPH oxidases axis as a potential therapeutic target 
to modify the vascular effects of obesity.  
A limitation of the current study is the lack of in vivo mechanistic data linking WNT5A 
overexpression with atherosclerosis. Although we demonstrated that high plasma 
concentrations of WNT5A were related to faster progression of coronary atherosclerosis and 
development of new coronary calcified plaques in humans, an in vivo experimental model 
would potentially prove causality of this association.  Further, prospectively designed, clinical 
studies are required to determine the prognostic value of circulating WNT5A as a biomarker 
for the prediction of vascular disease related outcomes (e.g., calcified plaque progression, 
clinical endpoints such as non-fatal myocardial infarction, stroke, cardiac mortality). Finally it 
remains unclear whether WNT5A secretion from the adipose tissue and/or WNT5A-reated 
vascular signalling could be targeted therapeutically, and whether such an intervention would 
have the potential to prevent the vascular complications of obesity. 
Obesity is associated with enhanced activation of non-canonical Wnt signaling in the human 
arterial wall resulting from a shift in the balance between WNT5A and SFRP5 both in the 
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circulation and in PVAT and up-regulation of the WNT5A receptors Fzd2 and 5 on the arterial 
wall. This results in USP17-mediated activation of RAC1 and downstream activation of 
vascular NADPH oxidases, leading to O2.- -induced migration of VSMCs. At a clinical level, 
WNT5A concentration is independently associated with the presence of CAD and progression 
of calcified coronary atherosclerotic plaque burden. These data identify UPS17 and WNT5A 
as rational targets for the prevention and /or treatment of vascular complications associated 




The aim of this work was to explore the role of AT-derived WNT5A in regulating vascular 
redox signalling and vascular disease progression in humans. We hypothesised that WNT5A 
would be upregulated in obesity and would be able to induce vascular NADPH oxidase 
activation via RAC1 signalling, which could have downstream redox signalling effects 
triggering vascular disease. 
To address these hypotheses, we first explored the associations between obesity, arterial O2.- 
generation and the bioavailability of WNT5A in the circulation and a variety of AT depots 
(ScAT, ThAT, PVAT) in a cohort of 1,004 patients undergoing cardiac surgery (study 1, see 
below). These were used to provide observational insights as to the relationship of WNT5A 
with arterial oxidative stress in the context of obesity. Power size calculations for these clinical 
studies indicated that we would need 933 patients to detect a 10% difference in arterial 
NADPH-stimulated O2.- between the low and high plasma WNT5A/SFRP5 tertile with α = 0.05 
and power of 0.90 assuming an SD of 100 RLU/sec/mg tissue.  
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The clinical link of circulating WNT5A with parameters of vascular disease (presence of CAD, 
calcified plaque progression, new onset calcification) was tested in a validation study of 70 
CAD patients matched with 70 non-CAD controls (study 2, see below) and a follow-up study 
of CCS monitoring in patients having undergone two cardiac CT scans, where baseline and 
follow-up CCS scores were evaluated and circulating WNT5A was quantified. With 70 patients 
per group, we could detect a difference of 10ng/mL in plasma WNT5A with α = 0.05 and power 
0.9 (assuming plasma WNT5A SD = 9ng/mL). 
Ex vivo mechanistic experiments were employed to test the direct signalling effects of WNT5A 
incubations on human arteries harvested during surgery, in a series of mechanistic experiments 
performed in a paired design for individuals patients. Based on previous work from our group, 
we estimated that with a minimum of 5 pairs of samples (serial rings from the same vessel) we 
would be able to identify a change of log(O2.-) by 0.48 with α = 0.05, power 0.9 and SD for a 
difference in the response of the pairs of 0.25. 
The effect of WNT5A on arterial O2.- production was validated with a short-term proof-of-
concept mouse experiment of global inducible Wnt5a overexpression upon doxycycline 
treatment. We estimated that with 5 mice per group we could detect a difference of 250 
RLU/sec/mg tissue in aortic O2.- with α = 0.05 and power 0.9 assuming an aortic NADPH-
stimulated O2.- SD of 120 RLU/sec/mg tissue).  
The integrated effects of WNT5A on vascular redox state and downstream redox signalling 
events such as cell migration were evaluated in vitro in primary VSMCs isolated from human 
vascular segments. Similarly to the ex vivo experiments, we estimated that with 5 pairs of wells 
we would be able to identify a change of 175 RLU/sec/μg protein in VSMC NADPH-
stimulated O2.- with α=0.05, power 0.9 and SD = 85 RLU/sec/μg protein. 
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Human study protocols were in agreement with the Declaration of Helsinki and all patients 
provided written informed consent prior to enrolment. All studies (clinical or experimental) 
were performed blinded. Human studies were approved by local research ethics committees 
(under RECs 11/SC/0140 and 15/SC/0545). All animal studies were conducted with ethical 
approval from the Local Ethical Review Committee and in accordance with the UK Home 
Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986).  
 
Human studies protocols 
Study protocols were in agreement with the Declaration of Helsinki and all patients provided 
written informed consent prior to enrolment. The demographic characteristics of the 
participants of all study arms are presented in table S1. Hyperlipidaemia and hypertension were 
defined according to the latest European Society Cardiology Guidelines (35, 36). Diabetes 
mellitus was defined according to the American Diabetes Association guidelines (37). Obesity 
was defined according to the Adult Treatment Panel (ATP) III guidelines (38). 
 
In vivo clinical studies (studies 1-3) 
Study 1 comprised 1,004 prospectively enrolled patients undergoing cardiac surgery [including 
coronary artery bypass grafting (CABG) and valve replacement/repair] at the John Radcliffe 
hospital, Oxford University NHS Foundation Trust, UK. Exclusion criteria included 
inflammatory, neoplastic, renal, or hepatic diseases. Fasting blood samples were obtained on 
the morning of surgery and were used for plasma isolation for circulating biomarker 
measurements. During surgery, segments of the IMA with its surrounding PVAT, ThAT from 
the paracardial region, and ScAT from the chest were collected, transferred to the lab on ice, 
21 
 
and processed for ex vivo experiments, vasomotor studies, and measurement of vascular O2.-. 
Study 2 included 70 individuals with CAD and 70 controls without CAD (confirmed with 
coronary CT angiography). Individuals were matched for age, gender, and BMI for cross-
sectional studies comparing circulating WNT5A and SFRP5. Study 3 consisted of 68 
individuals that underwent two non-contrast CT scans 3-5 years apart (48.5±5.8 months), to 
study progression of atherosclerotic disease in the coronary arteries. The development of new 
calcification and the progression of existing calcified atherosclerotic plaques were compared 
between the two scans.   
 
Ex vivo studies with human vessels (study 4) 
The human ex vivo study (study 4) included 94 patients undergoing cardiac surgery at the John 
Radcliffe hospital, Oxford University NHS Foundation Trust, UK. Patients were prospectively 
recruited and patients with inflammatory, neoplastic, renal or hepatic diseases were excluded. 
Human IMA and saphenous vein (SV) segments were collected during surgery and transferred 
to the lab on ice. IMA samples were processed in the lab as explained in relevant sections, 
subjected to ex vivo incubations and ultimately used for vascular O2.- quantification, vasomotor 
studies, biopterin measurements and downstream signaling evaluation as described later.  
 
In vivo animal studies 
A doxycycline-inducible WNT5A knock-in mouse model was used to determine the in vivo 
effects of WNT5A on vascular NADPH oxidases activity. FVB/N Tg(tetO- Wnt5a)17Rva/J 
mice were obtained from Jackson Laboratories (stock #022938), and crossed to mixed 
background C57BL/6, 129/SV, FVB CAGG-rtTA (generated by Dr Lukas Dow in the lab of 
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Dr Scott Lowe at Memorial Sloan Kettering Cancer Centre, USA) (39). Mice were backcrossed 
to C57BL/6 background seven times prior to the study. TetO-Wnt5a+ and rtTA+ mice were then 
crossed obtaining double transgenic mice, rtTA+ single transgenic mice were kept as control 
animals. 2mg/mL doxycycline hyclate (J60579, Alfa Aesar) was administered, to both double 
transgenic tetO- Wnt5a+/rtTA+  and control tetO-Wnt5a–/rtTA+ animals via the drinking water, 
containing 5% sucrose overnight to induce Wnt5a expression.  Considerable weight loss (up to 
~15% of body weight) was observed after three days of doxycycline treatment, therefore this 
mouse model was not suitable for long-term experiments as per local committee ethics. 
Overnight doxycycline treatment induced minor weight loss and did not compromise the 
welfare of the animals. DNA extracted from experimental animal ear notches was used for 
genotyping with the following PCR primers: 
C57BL/6, FVB CAG-rtTA 
CCM 5’- CGAAACTCTGGTTGACATG - 3’ 
CTG 5’- ATGCCCTGGCTCACAAATAC - 3’ 
CWT 5’- TGCCTATCATGTTGTCAAA – 3’ 
C57BL/6, FVB/N Tg(tetO- Wnt5a)17Rva/J 
17815 5’- ACAAAGACGATGACGACAAGC – 3’ 
17816 5’- CGCACCTTCTCCAATGTACTG – 3’ 
oIMR7338 5’- CTAGGCCACAGAATTGAAAGATCT – 3’ 
oIMR7339 5’ – GTAGGTGGAAATTCTAGCATCATCC – 3’ 
Mice were housed in a specific pathogen-free environment, in Tecniplast Sealsafe IVC cages 
(floor area 542 cm2) with a maximum of six other mice. Mice were kept in a 12 h light/dark 
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cycle and in controlled temperatures (20–22°C) and fed normal chow and water ad libitum. A 
detailed phenotyping of the mouse model is presented in fig. S4. 
 
Blood Sampling and Circulating Biomarker Measurements 
Humans 
Preoperative venous blood samples were collected from subjects of Study 1 after 8h of fasting 
and in particular on the morning of surgery as previously described (40). Blood samples were 
also collected from subjects of Study 2 after 8h of fasting upon admission. Similarly, blood 
samples from Study 3 participants were collected after 8h of fasting just prior to the cardiac 
CT scans. After centrifugation at 2000 g at 4°C for 15 min, plasma was collected and stored at 
−80 °C until assayed. Plasma WNT5A and SFRP5 were measured by using commercially 
available ELISA kits (Cloud Clone Corp, catalogue number SEP549Hu and MyBiosource, 
catalogue number MBS702373 respectively) following the manufacturer’s instructions. 
 
Mice 
900 μl blood was drawn from the vena cava into a syringe containing sodium heparin. Blood 
samples were centrifuged for 15 minutes at 3,000 rpm at room temperature. Plasma was 
subsequently centrifuged for 5 minutes at 13,000 rpm to remove remaining cells and platelets 
and immediately frozen at -80°C. Plasma WNT5A was measured by using a commercially 





Human Adipose Tissue and Vessel Harvesting 
Internal mammary artery (IMA) samples were harvested with a “no touch” technique with their 
perivascular tissue (PVAT) at the time of CABG as we have described previously (42). 
Vascular segments were transferred into oxygenated (95% O2/5% CO2) ice-cold Krebs Hensleit 
buffer and the vessel lumen was flushed gently by using an insulin syringe to remove blood. 
Each vessel was separated from its surrounding adipose tissue in the lab, under magnification 
by the same operator, to limit the between-patients variability. The same anaesthetics were 
used in all cases, and each sample was always obtained at the same stage of the operation, to 
limit inter-patient variability. ThAT and ScAT specimens were collected during surgery, then 
snap-frozen in TRI reagent (Sigma, catalogue number T9424) and stored at -80oC until used 
for RNA isolation. 
 
Transcriptome Profiling of WNT5A-Treated VSMCs 
Treatments and RNA Extraction 
VSMCs isolated from five individual patients were incubated 8 hours with 100 ng/mL WNT5A 
or 100 U/mL peg-SOD. Patients were selected to be obese and without diabetes mellitus, 
allowing us to evaluate the integrated effects of WNT5A in the clinically relevant setting of 
obesity. RNA was extracted from VSMCs using the MagMAX mirVana total RNA isolation 
kit (Thermo Fischer Scientific, Catalogue Number A27828) as mentioned earlier, and 
processed for high throughput gene expression profiling. 
GeneChip Human Transcriptome Array 2.1 
The genome-wide expression profiling was carried out at the High Throughput Genomics 
Wellcome Trust Centre for Human Genetics (Oxford, UK). RNA samples were processed 
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using the Affymetrix GeneChip WT PLUS Reagent kit, the manual target preparation for 
GeneChip whole transcript expression arrays.  The labelled ss-cDNA were then hybridised to 
the Affymetrix HuGene-2.1-st Array Plate and processed on the Affymetrix GeneTitan 
platform. The microarray data generated by this study have been submitted to GEO depository 
under ID GSE109859. 
 
Statistical analysis 
Continuous variables were tested for normal distribution using the Kolmogorov-Smirnov test. 
Non-normally distributed variables are presented as median[25th-75th percentile] and whiskers 
(Tukey). Normally distributed variables are presented as mean±SEM. Comparisons of 
continuous variables between two groups were performed using unpaired t test or Man-
Whitney U-test as appropriate, while comparisons between 3 or more groups were performed 
using one-way ANOVA or Kruskal-Wallis followed by Bonferroni or Dunn’s post hoc 
correction for multiple comparisons. Paired comparisons were performed using paired t test or 
Wilcoxon signed-rank test as appropriate. For between-groups serial changes we used two-way 
ANOVA for repeated measures with interaction terms as presented in the figure legends. 
To examine whether the association between obesity and vascular NADPH oxidase activity is 
independent of WNT5A/SFRP5 expression in PVAT, we performed multivariate linear 
regression where NADPH-stimulated O2.- was used as dependent variable and obesity 
classification, age, sex, diabetes, hypertension and smoking (with/without the addition of 
WNT5A/SFRP5 expression tertiles in PVAT) were used as independent variables. The relevant 
standardised beta coefficients are presented. To address whether plasma WNT5A, SFRP5 and 
the ratio of the two were independently associated with the presence of CAD in the nested case-
control study 2, we performed multivariate linear egression in which the presence of CAD was 
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used as dependent variable and hypertension, hyperlipidaemia, smoking and plasma WNT5A 
or SFRP5or  WNT5A/SFRP5 ratio were used as independent variables.  The standardized beta 
(Bstand) is presented for each variable. To examine whether coronary calcified plaque 
progression or new onset calcification were associated with plasma WNT5A, we performed 
multivariate linear regression where calcified plaque progression and new onset calcification 
were used as dependent variables and plasma WNT5A, age and sex were used as independent 
variables. All statistical tests were two-tailed and were performed using SPSS version 20.0. 
P<0.05 was considered statistically significant. 
With regards to microarray data processing, normalisation, quality control and differential gene 
expression analysis was performed with the Affymetrix Transcriptome Analysis Console (TAC 
4.0) Software. The statistical comparisons between treatments was done following a repeated 
measures model for the individual patients.WNT5A pathway enrichment analysis was carried 
out in ConsensusPathDB-human with differentially expressed genes (DEGs) (WNT5A -treated 
vs. untreated-controls) that displayed fold change (linear)>1 or <-1 and a p-value (condition 
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Fig. 1. Gene expression of Wnt ligands in adipose tissue and plasma concentration of 
WNT5A/SFRP5 in obesity. (A-C) Gene expression of the 19 Wnt ligands in human (A) 
35 
 
perivascular (PVAT), (B) thoracic (ThAT), and (C) subcutaneous (ScAT) AT in n = 54 patients 
of study 1. (D-F) Circulating plasma concentrations of (D) WNT5A (range: 1 to 112 ng/ml), 
(E) decoy receptor SFRP5 , and (F)  WNT5A/SFRP5 ratio in individuals of study 1. (G-I) Gene 
expression of (G) WNT5A, (B) SFRP5, and (C) the ratio of WNT5A/SFRP5 in ThAT of study 
1 participants. Study 1 participants per group: BMI: ≤20Kg/m2: 25; 20.1-24.9 Kg/m2: 217; 25-
29.9 Kg/m2: 432; 30-34.9 Kg/m2: 233; ≥35 Kg/m2: 57.  Data are presented as mean ± SEM (A-
C) or median[25th-75th percentile] (D-I). P values in (A-C) are calculated by Friedman tests; P 
values in (D-I) are calculated by Kruskal Wallis tests. AT: adipose tissue; SEM: Standard error 
















Fig. 2. Interactions between obesity, WNT5A/SFRP5, and vascular disease. (A-C) Gene 
expression of (A) WNT5A, (B) SFRP5, and (C) the ratio of WNT5A/SFRP5 in IMAs according 
to BMI. (D-F) Gene expression of (D) WNT5A, (E) SFRP5, and (C) the ratio of WNT5A/SFRP5 
in PVAT according to BMI. (G-I) Gene expression of Wnt receptors (G) FZD2, (H) FZD5, 
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and (I) ROR1 in IMAs according to BMI . (J-L) Circulating plasma concentrations of (J) 
WNT5A, (K) SFRP5, and (L) WNT5A/SFRP5 ratio in patients with CAD and healthy controls 
(n = 70). (M) Table of multivariable regression analysis of the association of circulating 
WNT5A, SFRP5, WNT5A/SFRP5, cardiovascular risk factors, and the presence of CAD in 
study 2 (n = 70). (N) Plasma WNT5A concentration in patients with or without coronary 
calcium score (CCS) progression (ΔCCS≥1ΗU, 61.8[22.6-234.6], n = 68, study 3). (O) Plasma 
WNT5A concentration in patients with or without  new onset calcification (follow-up 
CSS:21.7[2.5-27.1], n=38). (N-O) presented as median[25th-75th percentile]. Data are 
presented as median[25th-75th percentile]. P values in (A-N) are calculated by Kruskal Wallis 
tests. Study 1 participants with IMA/PVAT samples available for panels A-I were: 
BMI<25Kg/m2: 33; 25-29.9Kg/m2: 77; 30-30Kg/m2:42; >35 Kg/m2:13. IMA: internal 














Fig. 3. WNT5A regulates vascular redox state in humans. (A) Basal and (B) NADPH-
stimulated superoxide (O2.-) production in internal mammary artery (IMA) segments according 
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to BMI (study 1). (C) Basal and (D) NADPH-stimulated O2.- production in IMAs according to 
circulating plasma WNT5A/SFRP5 ratio tertiles. (E) Basal and (F) NADPH-stimulated O2.- 
production in IMAs according to WNT5A/SFRP5 ratio tertiles in perivascular adipose tissue 
(PVAT). (G) Basal and (H) NADPH-stimulated O2.- production in IMAs according to 
WNT5A/SFRP5 ratio tertiles in internal mammary arteries (IMAs). (I) Basal, (J) NADPH-
stimulated, and (K) Vas2870-inhibitable O2.- production in IMAs in the presence and absence 
of WNT5A and SFRP5 in ex vivo IMA segments (n =5-10 pairs per intervention). (L) 
Dihydorethidium (DHE) staining in IMAs incubated with or without Vas2870 , WNT5A, and 
SFRP5 (specific oxidised DHE fluorescence corresponds to the red signal; the green signal 
reflects tissue autofluorescence). (M)  Basal or (N) NADPH-stimulated O2.- production in 
IMAs in pre-incubated (preinc.) with Vas2870  and treated with WNT5A (n = 5-10 pairs per 
intervention). (O) Circulating plasma WNT5A (n = 11-14 mice per group) and (P) basal O2.-, 
(Q) NADPH-stimulated O2.-, and (R) Vas2870-inhibitable O2.- in TetOWNT5A mouse aortae 
(O: n = 5 per group, P-R: n = 7 per group). Data are presented as median[25th-75th percentile] 
(A-H) or as mean ± SEM (I-K, N-R). P values in (A-H) are calculated by Kruskal Wallis tests; 
*P < 0.05 vs control in (I-J) and (M-N) by Wilcoxon signed-rank tests; P values are calculated 










Fig. 4. WNT5A triggers RAC1activation, resulting in NADPH oxidases in the human 
vascular wall. Fold change of phosphorylated c-jun N-terminal kinase (JNK) in (A) human 
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internal mammary artery (IMA) segments ex vivo (n=5 of paired samples) ) in the presence 
and absence of WNT5A and SFRP5 and in (B) Wnt5a+/rtTA+ mouse aortae in vivo (n = 5 per 
group. (C) Activation of RAC1 and membrane translocation of (D) RAC1 and (E) P47phox 
subunits of NADPH oxidases in human IMAs (n = 5 of paired samples) ex vivo in the presence 
or absence of WNT5A and SFRP5. (F) Basal, (G) NADPH-stimulated, and (H) Vas2870-
inhibitable superoxide (O2.-) anion production in IMA segments with or without WNT5A and 
NSC23766, a specific RAC1 inhibitor (n = 8-10 pairs per intervention). (I) Basal, (J) NADPH-
stimulated, and (K) Vas2870-inhibitable superoxide (O2.-) anion production in Wnt5a+/rtTA+ 
mouse aortae incubated with or without WNT5A and NSC23766 (n = 5-7 per group). Data are 
presented as mean ± SEM.*P < 0.05 vs control in all panels by Wilcoxon signed rank tests. 














Fig. 5. WNT5A is secreted by adipocytes and enhances NADPH oxidase activity in human 
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Jun N-terminal kinase (JNK) (n = 5), (B) activated RAC1 (n = 5), and (C) activated β-catenin 
(n = 6) in VSMCs in the presence or absence of WNT5A and SFRP5. (D) Basal, (E) NADPH-
stimulated, and (F) Vas2870-inhibitable superoxide (O2.-) production in VSMCs (n = 6-11 pairs 
per intervention) in the presence or absence of WNT5A and SFRP5. (G) Knock-down of 
WNT5A in human immortalised pre-adipocytes (n = 3). (H) Basal and (I) gp91 dstat-inhibitable 
O2.- production in VSMCs co-cultured with or without  WNT5A -KO preadipocytes displayed 
lower (n = 5). Data are presented as mean ± SEM *P < 0.05 vs control by Wilcoxon signed 

















Fig. 6. The pro-oxidant effects of WNT5A in human vascular smooth muscle cells are 
mediated by Frizzled 2 (Fzd2) and Frizzled 5 (Fzd5) receptors. (A) Fluorescence 
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nuclei stained with DAPI (blue signal), (B) fexpression old change, and (C) Western blotting 
of transfection efficiency of knock-down of FZD2 and FZD5 genes in VSMCs (~96% 
downregulation of FZD2, ~65% downregulation of FZD5; n = 3). (D) Basal, (E) NADPH-
stimulated, and (F) Vas2870-inhibitable O2.- production in siRNA-FZD2-treated VSMCs (n = 
5-6 pairs per intervention) in the presence or absence of WNT5A. (G) Basal, (H) NADPH-
stimulated, and (I) Vas2870-inhibitable O2.- production in siRNA-FZD5-treated VSMCs (n = 
6 pairs per intervention) in the presence or absence of WNT5A. Data are presented as mean ± 
SEM. *P < 0.05 vs control by Wilcoxon signed ranks tests (D-I) or paired t-test (B). SEM: 
















Fig. 7. WNT5A triggers redox-dependent migration of human vascular smooth muscle 


















































































































































































































































































change > 1 or < -1, P ≤ 0.05) in  WNT5A -treated VSMCs from n = 5 patients. DEGs were 
annotated with cell motility function in Gene Ontology (GO) database. (B) Enriched signaling 
pathways of WNT5A cell-motility DEGs identified through ConsensusPathDB. (C) 
Microscopy and (D) quantitation of Boyden chamber assay for cell migration, using VSMCs 
treated with or without recombinant WNT5A and SFRP5 (n = 30). (E) Proliferation of VSMCs 
in the presence of WNT5A (n = 6-9 per time point per group, evaluated by two-way ANOVA 
for repeated measures). Data are presented as mean ± SEM in panels D-E. *P < 0.05 vs control 
by Wilcoxon signed rank tests; +P < 0.05 vs WNT5A by Wilcoxon signed rank test. SEM: 
















 Fig. 8. USP17 as a link between WNT5A and vascular redox signaling. (A) Migration of 
VSMCs incubated with peg-SOD, an intracellular scavenger of superoxide (O2.-) production, 
(n = 5-8 pairs per intervention) and treated with WNT5A. (B) A subset of the WNT5A cell-
motility differentially expressed genes of the microarray analysis were at least partially rescued 
by superoxide (O2.-) anion scavenging with superoxide dismutase (peg-SOD) resulting in p-
values>0.05 (n = 5 pairs, genes presented by descending mean fold change). (C) USP17 
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expression in VSMCs incubated with peg-SOD and treated with WNT5A (n = 10). (D) RAC1 
activation in HeLa cells transfected with shUSP17 and treated with WNT5A (n = 8). Data are 
presented as mean ± SEM in panels A, C and D.  *P < 0.05 vs control by Wilcoxon signed rank 
test in panels A & C.+P<0.05 vs untreated empty vector control by Wilcoxon signed rank test; 
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In vitro studies 
Primary vascular smooth muscle cell (VSMC) isolation & characterisation 
Human saphenous vein (SV) explants from 46 patients (38 males, 8 females) were washed in 
phosphate-buffered saline (PBS) and the adventitia layer was removed. Vessels were cut 
longitudinally to expose the endothelium, which was removed using a scalpel. The tissue was 
washed in PBS and digested with 0.25% trypsin for 10min. The digested tissue was diced into 
1mm2 sections and seeded in Dulbecco’s modified eagle media (DMEM)+20% FBS. VSMCs 
were grown in Media 231 supplemented with smooth muscle growing supplement (SMGS) 
(Life Technologies Ltd) in a cell culture incubator at 37oC and 5% CO2 following the first 
passage.  
For characterisation purposes, VSMCs were plated on a 6-well plate for 24h, culture media 
was removed and cells fwere ixed with 4% paraformaldehyde. To permeabilise the cells, 0.2% 
Triton in PBS was added for 10min at room temperature and the cells were then washed thrice 
with PBS and blocked with 10% bovine serum albumin (BSA). Cells were incubated overnight 
at 4°C with mouse monoclonal anti-CD31 (Sigma, P8590) or mouse monoclonal anti-α-smooth 
muscle actin (Sigma, A5228) primary antibody and secondary antibody goat-anti mouse Alexa 
Fluor 488 conjugated (ab150113, Abcam) for 1 hour at room temperature. Following 3 washes 
with PBS, the cells were dried and mounted with Slow Fade Gold Anti Fade with DAPI 
(S36939, ThermoFisher) before visualization with fluorescence inverted microscope (Olympus 






VSMCs were co-cultured with human pre-adipocytes using trans-well plate (0.4 µm 
polycarbonate filter, Corning) for 24 h. Human pre-adipocytes were cultured in the bottom 
chamber and VSMCs in the top one.  
Cell proliferation assay 
1 × 104 cells per well were seeded in a 96 well plate in 100 μL of culture medium and grown 
at 37 °C in the presence or absence of WNT5A 100 ng/mL or SFRP5 300 ng/mL. At the 
indicated incubation time points (24, 48, and 72 h), 20 μL CellTiter 96 AQueous One Solution 
Reagent (Promega) was added to each well and the plates were incubated for 2 h at 37 °C. 
Subsequently, absorbance at 490 nm was measured using a 96-well plate reader, which served 
as an indicator of the number of viable cells in each well. 
Cell migration assay 
Cell migration was assessed in a modified Boyden chamber (Costar), in which two chambers 
were separated by a polycarbonate membrane (pore diameter, 8.0 μm). VSMCs were grown 
overnight in serum-free medium-231; the following day, 3 × 104 cells were seeded into the 
trans-wells with a membrane placed in the bottom. Medium-231 containing 0.1% FBS and 
different interventions: 100 ng/mL WNT5A, 300 ng/mL SFRP5and 100 IU/mL pegylated 
superoxide dismutase (peg-SOD, Sigma) was added to both the upper and lower compartment 
of the Boyden chamber. The cells were allowed to migrate for 8 h at 37°C in this setting. 
Thereafter, medium was discarded, cells were fixed with 4% paraformaldehyde (PFA) and 
stationary cells removed with a cotton bud. Cells were stained with 0.5% crystal violet and the 
number of cells having migrated through the membrane was evaluated in a light microscope 
by cell counting. Considering that WNT5A (and all other interventions) were present in both 
compartments of the Boyden chamber at equal concentrations, these results should be 
53 
 
interpreted in the context of the ability of WNT5A to stimulate the motility and migration 
capacity of VSMCs, not its ability to act as a chemoattractant. 
Wound Healing assay 
VSMCs were trypsinized and re-suspended in PBS to a concentration of 5x105 cells/mL. 70 
µL of cell suspensions were added to each chamber of the ibidi Culture-Insert (cat. IB-81176), 
where cells were allowed to grow until confluency. The plastic insert was removed after 24h 
of serum starvation and, medium was replaced with DMEM containing 0.1% fetal bovine 
serum (FBS) following two washes with PBS and cellular monolayers were allowed to heal for 
15 h. Photographs of central wound edges per condition were taken at time zero and at the 
indicated time points using a digital camera. 
VSMC phenotypic switch 
VSMCs were treated with recombinant WNT5A 100ng/mL or vehicle for 8h following 
overnight serum starvation, and contractile-to-synthetic phenotypic switch was evaluated by 
quantifying the mRNA expression of established markers (smooth muscle α2 actin-ACTA2, 
transgrelin-TGLN, smooth muscle protein 22α-SM22α, metalloproteinase 9-MMP9 and MMP 
inhibitors TIMP1 and TIMP2) as described below. 
Transfection studies with Fz2 and Fz5 siRNA 
Fzd2, Fzd5 siRNA (ON-TARGET plus SMART pool) and negative control siRNA (ON-
TARGET plus non-targeting pool) were purchased from Dharmacon and used to knock-down 
Fzd2 and Fzd5 receptors in human VSMCs, respectively. Briefly, 1x106 cells were seeded in a 
6 well plate for 24h, and medium was replaced by Optimem on the day of transfection. 
Lipofectamine RNAiMax (Thermo Fisher Scientific) was used to transfect VSMCs with 100 
pmoles of siRNA according to the instructions provided by the manufacturer. 24 h post-
transfection, Optimem was replaced by Medium 231 plus SMGS. To test the transfection 
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ability as well as the toxicity of lipofectamine RNAiMax on primary VSMCs, BlockiT Alexa 
Fluor Red Fluorescent control (14750100, ThermoFisher) was used as positive transfection 
control. 
Transfection studies with shUSP17 
HeLa cells from passage 10-17 were cultured in growth medium DMEM with 10% FCS, 1% 
penicillin/streptomycin, and 200 mM L-glutamine at 37 °C in a 5% CO2 humidified incubator. 
Cells were starved overnight, and transfected with pRS-USP17 shRNA (TG321147, Origene 
Technologies) using FuGENE6 (E2691, Promega). 
Total RNA was isolated using Trizol, followed by chloroform and isopropanol extraction, 
washing by ethanol and dissolving in DEPC-H2O. USP17 mRNA expression was detected as 
described previously (18). Briefly, 1 μg total RNA was applied using the OneStep RT–PCR kit 
(210210, Qiagen). The primer sets for USP17 are: 
 5′-CAGTGAATTCGTGGGAATGGAGGACGACTCACTCTAC-3′ (forward) 
5-AGTCATCGATCTGGCACACAAGCATAGCCCTC-3′ (reverse)  
We used β-actin as a housekeeping gene by the following primers:  
5′-GGACTTCGAGCAAGAGATGG-3′ (forward)  
5′-AGCACTGTGTTGGCGTACAG-3′ (reverse) 
Clones with undetectable USP17 expression were used for 8h incubations with WNT5A 





Coronary calcium score (CCS) quantification in study 3 
At both time points (baseline and follow-up) a non-contrast prospectively ECG-triggered axial 
acquisition CT scan was obtained (2.5-3.0 mm axial slice thickness, tube energy of 120 kV) 
with the carina and the diaphragm used as cranial and caudal landmarks respectively. In all 
patients, the baseline scan was acquired using a 64-slice LightSpeed Ultra CT scanner (General 
Electric Healthcare), whereas all follow-up scans were performed in a 320-slice Aquilion One 
scanner (Toshiba Medical Systems). CCS was measured on a dedicated workstation (Aquarius 
Workstation V.4.4.13, TeraRecon Inc., Foster City) according to the Agatston method (41). 
Coronary calcification progression was defined as any change in CCS ≥ 1, while new onset 
calcification was evaluated in those patients having CCS=0 at the time of the baseline scan. 
Ex Vivo incubations of human vascular tissue 
All ex vivo incubations of human tissue were performed as we have previously described 
(40,43). Fresh, intact human IMA samples were cut into sequential rings and opened 
longitudinally to expose the endothelial surface. Each segment was then equilibrated for 45 
minutes in oxygenated (95% O2/5% CO2) Krebs-HEPES buffer (pH 7.4) at 37°C, where carrier 
(sterile PBS), WNT5A 100ng/mL (R&D Systems, 645-WN/CF) or SFRP5300ng/mL (R&D 
Systems, 6266-SF) was added. The vascular segments were then used fresh for superoxide (O2.-
) quantification or snap-frozen in -80oC until processed later. In a subset of patients, Vas2870 
ex vivo 20min incubation preceded the WNT5A treatments to pre-inhibit NADPH-oxidases. 
For the Rac1 inhibition experiments, human IMA and mouse aortae were pre-incubated with 
NSC23766 100μM (R&D systems, catalogue number 2161) for 15min prior to any experiment. 
56 
 
For the visualisation of vascular O2.- production, human IMA were incubated in the presence 
or absence of WNT5A as described earlier, and snap-frozen in optical coherence tomography 
(OCT) medium until used for oxidative fluorescent microtopography as explained later. 
 
Vasomotor studies 
All vasomotor studies were performed as we have previously described (43). Briefly, serial SV 
rings were mounted on Radnotti organ bath chambers and equilibrated for 30 min in 37oC, 95% 
O2/5% CO2 in Krebs Henseleit buffer (NaCl 120 mM, KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 
1.2 mM, KH2PO4 1.2 mM, NaHCO3 25 mM, glucose 5.5 mM, pH = 7.4). Endothelial function 
was assessed by endothelium-dependent, acetylcholine (ACh)-mediated dose-response 
relaxations (10-9 M to 3x10-6 M) after phenylephrine (PE) 3x10-6 M pre-constriction. 
Endothelium-independent vasorelaxations were also evaluated in the same rings after in-
chamber eNOS inhibition (by LNAME), and endothelium-independent vasorelaxations were 
evaluated by sodium nitroprusside (SNP, 10-10 M to 10-6 M). All ex vivo incubations (WNT5A 
100 ng/mL and/or SFRP5 300 ng/mL) were performed in the organ bath chambers for 45min 





Production of O2.- was measured using a lucigenin (5 μmol/L)-enhanced chemiluminescence 
assay as we have previously described (40). VSMCs were incubated with WNT5A 100 ng/mL 
or SFRP5300 ng/mL for 30 min, then scraped in ice-cold buffer (KH2PO4 50mM, EGTA 1 
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mM, sucrose 150 mM, pH = 7) in the presence of a protease inhibitor cocktail (Roche Applied 
Science) and lysed using an ultrasound bath. The contribution of NADPH-oxidases activity to 
the production of O2.- was quantified in the presence of NADPH 400 μmol/L (NADPH-
stimulated O2.-). Vas2870 (a specific pan-NADPH-oxidases inhibitor (40)) was also used to 
quantify the Vas2870-inhibitable O2.- as a more specific index of NADPH-oxidases activity. 
Vas2870 was routinely used as part of the standard assay procedure to improve the specificity 
of the technique towards NADPH-oxidases, not as a biological incubation. 
Vascular tissue 
Vascular O2.- production was routinely measured in fresh, intact human IMA and in selected 
mouse aorta segments by using lucigenin (5 μmol/L)-enhanced chemiluminescence, as we have 
described previously (40, 43). Vessels were opened longitudinally to expose the endothelial 
surface and equilibrated for 20 minutes in oxygenated (95% O2/5% CO2) Krebs-HEPES buffer 
(pH=7.4) at 37°C. The contribution of NADPH-oxidases activity to the production of O2.- was 
evaluated in the presence of NADPH 100 μmol/L and by quantifying the Vas2870-inhibitable 
O2.-. The Pan-NOX inhibitor Vas2870 was routinely used as part of the standard assay 
procedure to define the specific fraction of the chemiluminescence signal derived from NOXs, 
improving the specificity of the technique towards NADPH-oxidases, as we have previously 
described (40, 43).  In a specific experiment aiming to test whether the effect of WNT5A on 
vascular O2.- is conditional upon activation of NADPH-oxidases, the human arterial segments 
were pre-incubated with Vas2870 prior to exposure to WNT5A, as part of the actual 
experimental design, as clearly stated in relevant sections.  
The coupling status of eNOS was assessed by quantification of the difference in arterial O2.- 
generation before and after addition of N(G)-Nitro-L-arginine methyl ester (LNAME, 1mM). 
LNAME is an eNOS inhibitor, therefore reduction of vascular O2.- after LNAME incubation 
suggests that eNOS is a source of O2.- (therefore predominantly uncoupled), while increase of 
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O2.- following inhibition of eNOS by LNAME, suggests that the enzyme is largely coupled, 
producing NO (which is a scavenger of O2.-). The LNAME-inhibitable O2.- is therefore a 
measure of eNOS uncoupling, as we have described in the past (43, 44). 
 
Oxidative fluorescent microtopography 
 In situ O2.- production was determined in vessel cryosections with oxidative fluorescent dye 
dihydroethidium (DHE), as we have previously described (43). Serial IMA rings from n=4 
patients were incubated with/without WNT5A 100 ng/ml for 45 minutes and subsequently snap 
frozen in OCT. Cryosections (30 μm) were incubated with DHE (2 μmol/L for 5 minutes) in 
Kreps-Hepes buffer, with or without Vas2870 (400 μmol/L). Fluorescence images of the 
endothelium (x63, Zeiss LSM 510 META laser scanning confocal microscope) were obtained 
from each vessel quadrant. In each case, segments of vessel rings (± Vas2870) were analysed 
in parallel with identical imaging parameters in a blinded fashion. 
Arterial biopterin measurements 
Vascular BH4, BH2 and biopterin (B) content was quantified by HPLC followed by 
electrochemical (for BH4) and fluorescent (for BH2 and B) detection, as we have previously 
described (44, 45). Ex vivo incubated IMA rings were subjected to 3 freeze/thaw cycles in re-
suspension buffer (50 mM phosphate buffered saline, 1 mM Dithioerythritol (DTE), 1mM 
EDTA, pH=7.4) to induce endothelial cell lysis, debris was removed, and supernatant proteins 
were precipitated with ice-cold precipitation buffer (H3PO4 1M, trichloroacetic acid (TCA) 
2M and DTE 1mM). Samples were injected onto an HPLC system and quantified using 
sequential electrochemical and fluorescence detection. Quantification of BH4, BH2 and B was 
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by comparison with external standards (1nM – 0.1μM) prepared from 10 μM BH4, BH2 and B 
(Schircks, Zurich) stocks with serial dilutions in ice-cold re-suspension buffer. 
 
RNA Isolation, Reverse Transcription and Quantitative Real Time-Polymerase Chain 
Reaction (qRT-PCR)  
RNA isolation 
Total RNA was isolated by phenol:chloroform (1:5 ratio) separation followed by magnetic 
beads-based RNA purification on a KingFischer magnetic particle processor (Thermo Fischer 
Scientific) by using the MagMAX mirVana total RNA isolation kit (Thermo Fischer Scientific, 
Catalogue Number A27828). RNA concentration and quality was evaluated 
spectrophotometrically on NanoDrop ND-1000. 
Reverse transcription 
RNA was reverse-transcribed to cDNA by using SuperScript VILO mastermix (Thermo 
Fischer Scientific) following the Manufacturer’s instructions and extending the cDNA 
synthesis step to two hours at 60oC on a Veriti thermal cycler (ABI). 
Quantitative real-time PCR 
Quantitative real-time PCR was performed by TaqMan chemistry, using the standard universal 
TaqMan protocol as indicated by the Manufacturer, on a QuantStudio 7 flex real-time PCR 
system (Thermo Fischer Scientific). All samples were run in duplicates using 5 ng of cDNA as 
starting mass, and data was analysed by the Pfaffl method (46). Cyclophilin A (PPIA) was used 
as housekeeping gene for human AT and pre-adipocytes, while GAPDH was used as 
housekeeping gene for human vascular tissue and VSMCs.18S ribosomal RNA was used as 
housekeeping for mouse samples. The IDs of the TaqMan probes used are:  
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PPIA: Hs99999904_m1; GAPDH: Hs02786624_g1; SFRP5: Hs00169366_m1; WNT5A: 
Hs00998537_m1; WNT5B: Hs01086864_m1; WNT1: Hs00180529_m1; WNT3A: 
Hs00263977_m1; WNT3: Hs00902257_m1; WNT9A: Hs01573829_m1; WNT9B: 
Hs00287409_m1; WNT10A: Hs00228741_m1; WNT10B: Hs00928823_m1; WNT11: 
Hs01045906_m1; WNT6: Hs00362452_m1; WNT4: Hs01573505_m1; WNT2: 
Hs00608224_m1; WNT16: Hs00365138_m1; WNT2B: Hs00921614_m1; WNT7A: 
Hs01114990_m1; WNT7B: Hs00536497_m1; WNT8A: Hs00230534_m1; WNT8B: 
Hs00610126_m1; FZD2: Hs00361432_s1; FZD5: Hs00258278_s1; ROR1: Hs00938677_m1; 
ROR2: Hs00896176_m1; RYK: Hs00243196_m1; USP17: Hs00970729_g1; ACTA2: 
Hs05005341_m1; TAGLN: Hs01038780_m1; MMP9: Hs00957562_m1; TIMP1: 
Hs01092511_m1; TIMP2: Hs00234278_m1; NOX1: Hs01071088_m1; NOX2: 
Hs00166163_m1; NOX4: Hs01379108_m1; NOX5: Hs00225846_m1; WNT5A: 
Mm00437347_m1; 18S RNA: Mm04277571_s1 
 
Sample Preparation for Western Blotting 
Cell culture 
Protein extracts were obtained from 80% confluent cells, which were washed in cold PBS and 
lysed in RIPA buffer (Cell Signalling) containing proteases and phosphatases inhibitors 
(Roche). Protein concentrations were determined using the BCA assay (Pierce), with albumin 
as standard. 
Vascular tissue processing 
Human IMA segments and mouse aortic tissue were homogenised in ice-cold RIPA buffer 
(Cell Signalling) supplemented with proteases and phosphatases inhibitors (Roche) by using a 
TissueLyser LT (Qiagen). Protein concentrations were determined using the BCA assay 




20μg of denatured protein extracts were analysed by SDS/PAGE on 4-20% polyacrylamide 
gradient gel, and the proteins were then transferred to nitrocellulose membranes (Amersham). 
For detection of immuno-reactive bands, ECL select Western Blotting Detection Reagent 
(Amersham) was used. Western blots were quantified using Image Lab Bio-rad software 
integrated density analysis. The primary antibodies used were: rabbit polyclonal anti-Nox1 
(ab131088, Abcam, 1:1,000), rabbit monoclonal anti-Nox2 (EPR6991, Abcam, 1:5,000), rabbit 
monoclonal anti-Nox4 (ab109225, Abcam, 1:1,000), anti-anti-Nox5 ( HPA019362, Sigma, 
1:1,000), rabbit monoclonal anti p-SAPK/JNK (Thr183/Tyr185) (4671, Cell Signalling, 
1:500), rabbit monoclonal anti-SAPK/JNK (9258, Cell Signalling, 1:500), rabbit polyclonal 
anti-frizzled 2 (Abcam, ab52565, 1:1,000), rabbit polyclonal anti-frizzled 5 (06-756, Millipore, 
1:1,000), rabbit monoclonal anti- WNT5A  (C27E8, Cell Signalling, 1:1,000) mouse 
monoclonal anti-active β catenin (05-665, Millipore, 1;1,000) and mouse anti-GAPDH HRP-
conjugated (G9295, Sigma 1:20,000). HRP-conjugated anti-rabbit (A9169, Sigma, 1:10,000) 
and HRP-conjugated anti-mouse (A9044, Sigma, 1:15,000) were used as secondary antibodies 
as appropriate. 
 
Rac1 activation assay 
Rac1 activation assay was detected using an active rac1 detection kit (Cell Signalling). VSMCs 
or human IMA segments were lysed or homogenised respectively, using the lysis buffer 
provided by the kit, supplemented with protease and phosphatase inhibitors. Lysates (500ug) 
were then incubated with glutathione resin and GST-PAK1-PBD according to the 
manufacturer’s specific instructions (Cell Signalling). Western blot analysis was performed 
using mouse monoclonal anti-Rac1 (1:1,000) primary antibody and HRP-conjugated anti-
mouse (1:15,000) secondary antibody. 
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shRNA lentiviral particles transduction in immortalised pre-adipocytes 
An immortalised human pre-adipocyte cell line from subcutaneous abdominal adipose tissue  
was kindly donated by Constantinos Christodoulides and Fredrik Karpe, generated as described 
by Todorčević et al. (47). Immortalized human pre-adipocytes were cultured in a 6 well-plate 
until 50% confluence. On the day of the infection, media was replaced with culture media 
containing 5 µg/mL of hexadimethrine bromide. Immortalized pre-adipocytes were transduced 
with the appropriate amount of shRNA lentiviral transduction particles to downregulate 
WNT5A at a multiplicity of infection of 100. 24 h post post-incubation, transduced cells were 
selected with 0.5 µg/mL puromycin. WNT5A downregulation was then confirmed by qRT-
PCR and Western blotting as described in relevant sections. 
 
WNT5A Secretion assay 
Human immortalised pre-adipocytes were grown to ∼90% confluence in T75 flasks, washed 
three times with PBS and cultured with 0.1% BSA. After 24 h, medium was collected and 
centrifuged at 10,000 g for 10 min. Supernatant was concentrated using Amicon Ultra-15 
centrifugal filter system 10KMWCO (Millipore) and centrifuged at 5,000 g at room 
temperature for 1h and concentrated supernatants were used for Western blotting. 
 
Evaluation of vascular RAC1 and P47phox membrane translocation 
Membrane translocation of RAC1 and P47phox in human IMA was estimated by differential 
centrifugation of vascular homogenates to isolate membrane proteins, and membrane-
translocated RAC1 or P47phox protein was determined by Western immunoblotting as we have 
previously described (8). Briefly, vascular segments were homogenized in ice-cold HEPES 
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buffer (HEPES 20 mM, 150 mM NaCl, and 1 mM EDTA, pH=7.4) supplemented with a 
protease inhibitor cocktail (Roche, UK). Debris was removed by centrifugation of the 
homogenates at 2,800 g at 4°C for 20 min, and the protein content of supernatants was 
evaluated by the Pierce BCA protein assay kit. 500 mg of total protein were adjusted to 200 μL 
for all samples, added into ultracentrifugation tubes and ultra-centrifuged at 100,000 g for 60 
min at 4°C to separate the cytosolic from the membrane proteins. Following removal of 
supernatants containing the cytosolic proteins, pellets were re-suspended in 35 μL of lysis 
buffer containing 1% Triton and left for 20 min on ice. Protein concentrations were then 






























Fig. S1.  WNT5A & SFRP5 expression data in subcutaneous adipose tissue (ScAT), 
internal mammary arteries (IMAs), and perivascular adipose tissue (PVAT). (A-C) The 
expression of WNT5A (A), SFRP5 (B), and WNT5A/SFRP5 (C) in subcutaneous AT (ScAT) 
according to BMI (Study 1, n=1,004, data presented as median[25th-75th percentile]). (D) The 
expression of WNT5A in IMAs compared to its expression in PVAT from study 1 (data 
presented as mean ± SEM). P values in (A-C) are calculated by Kruskal Wallis tests; P value 













Fig. S2. Ex vivo effect of WNT5A on NOX isoform gene expression in internal mammary 
arteries (IMA). Gene expression of NOX1, NOX2, NOX4, and NOX5 in internal mammary 
artery (IMA) segments (n = 5 pairs) with and without 8h ex vivo WNT5A incubation. Data 









Fig. S3: Association of plasma WNT5A/SFRP5 with arterial NOX expression. Circulating 
WNT5A/SFRP5 ratio according to arterial (internal mammary artery, IMA) expression of (A) 
NOX2, (B) NOX4and (C) NOX5in study 1. P values are calculated by Kruskal Wallis tests; 



















Fig. S4. Effects of WNT5A on endothelial function and endothelial nitric oxide synthase 
(eNOS) coupling.  (A) Endothelial nitric oxide (NO) bioavailability in human saphenous veins 
(SV) ex vivo in the presence of WNT5A and SFRP5, as assessed by acetylcholine (Ach) 
mediated vasorelaxation and (B) endothelium-independent vasorelaxations to sodium 
nitroprusside (SNP) (n = 3-4 patients per intervention). (C) Vascular superoxide O2.- production 
in human internal mammary artery segments the presence of  N(G)-Nitro-L-arginine methyl 
ester (LNAME) delta(eNOS inhibitor), WNT5A or/and SFRP5, an assay for endothelial nitric 
oxide synthase (eNOS) uncoupling (n = 4-6 patients per intervention). (D) eNOS co-factor 
tetrahydropterin (BH4), (E) total biopterin, and (F) BH4/total biopterins ratio in internal 
mammary artery segments in the presence of WNT5A and SFRP5 (n = 4-5 patients per 
intervention) . *P < 0.05 vs control by two-way ANOVA for repeated measures in (A). Data 
presented as mean ± SEM. *P < 0.05 vs control by Wilcoxon signed-rank tests for (C-F); P 




















Fig. S5.  Phenotyping of the TetO-Wnt5a rtTA mouse model. (A) Overexpression of Wnt5a 
in primary adipocytes from TetO transgenic mice following doxycycline 100 nM treatment 
(n=3); (B) Dose-dependent induction of Wnt5a overexpression in primary adipocytes from 
rtTA+/TetO-Wnt5a+ mice with doxycycline (n = 3); (C-K) Wnt5a overexpression amplitude 
in primary adipocytes (n = 3 per group) and a variety of tissues (n = 4-6 per group for all tissues) 
from TetO transgenic mice. * P < 0.05 vs control calculated by Mann Whitney U test (D-K) or 





Fig. S6. Phenotyping of isolated primary vascular smooth muscle cells (VSMCs). (A) 
Validation of vascular smooth muscle cell (VSMC) isolation efficiency by 
immunofluorescence staining for alpha smooth muscle actin (α-SM-actin) and PECAM-31, an 
endothelial cell marker (EA.hy296 cells used as endothelial cell marker controls); (B) NOX 





























Fig. S7.  WNT5A dysregulated genes and pathways and effects on vascular smooth muscle 
cell (VSMC) migration. (A) Hierarchical clustering of the differentially expressed genes 
(DEG, fold change >1 or <-1, P-value≤0.05) with and without WNT5A treatment in primary 
vascular smooth muscle cells (VSMCs) from n = 5 patients. The rows represent the genes and 
the individual patient samples are shown as columns (1 column per sample). The expression 
level of each gene (log2 -transformed) is represented as a colour continuously mapped on the 
colour scale provided. The dendrograms provide some qualitative means of assessing the 
similarity between genes and between patient samples. (B) Pathway enrichment analysis of the 
set of WNT5A DEGs identified statistically enriched signalling transduction pathways that 
control several vital cellular processes including cell growth, differentiation, development, 
apoptosis and migration. (C-D) Wound healing assay in WNT5A-treated VSMC (n = 6), data 








































Fig. S8. WNT5A and vascular smooth muscle cell (VSMC) phenotypic switch. (A) ACTA2 
(α2 smooth muscle actin, n = 9 pairs) expression in WNT5A-treated VSMCs; (B) TAGLN 
(transgrelin, n = 9 pairs) expression in WNT5A-treated VSMCs; (C) Expression of 
metalloproteinase 9 (MMP9, an MMP linked with atherosclerosis progression) relative to its 
inhibitors TIMP1 & 2 (tissue inhibitors of metalloproteinases) in WNT5A-treated VSMCs (n 
























Fig. S9.  Ubiquitin-specific protease 17 (USP17) as the top hit of WNT5A and USP17 
transfection in HeLa cells. (A) Volcano plot of the differential expression of all altered genes 
upon WNT5A treatment of vascular smooth muscle cells (VSMCs) (n = 5). (B) HeLa cell 
shUSP17 transfection (successfully transfected clone 4 was passaged and used for downstream 
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Fig. S10: Schematic diagram with proposed mechanism. WNT5A secreted from 
perivascular and remote adipose tissue (AT) depots reaches the human vascular wall via 
paracrine and endocrine routes respectively and exerts Frizzled 2 & 5 receptor-mediated effects 
depending on its balance with its decoy receptor SFRP5, an effect enhanced in obesity. In the 
vasculature, WNT5A induces GTP activation of RAC1 and membrane translocation of RAC1 
and P47phox subunits of NADPH oxidases isoforms such as NOX2. All these contribute to 
vascular disease progression. Crucially, we identify the GTPase USP17 as a regulator of 



































Table S1. Demographic characteristics of the study participants. T2DM: Type 2 diabetes 
mellitus; BMI: Body mass index; ACEi: Angiotensin converting enzyme inhibitor; ARB: 
Angiotensin receptor blocker; CCB: Calcium channel blocker Continuous variables are 
presented as mean±SD; **P < 0.01 vs CAD, ***P < 0.001 vs non-CAD by Chi-square tests. 
 
 Study 1 Study 2 Study 3 Study 4 
  Non-CAD CAD   
Participants (n) 1,004 70 70 68 94 
Age (years) 66.8±10.1 61.1±6.7 61.3±13 60.4±8.5 66.5±9.4 
Males (%) 81.3 42.9 47.1 39.7  83.0 
Hypertension (%) 70.6 22.9 78.6*** 27.9 71.3 
Hyperlipidaemia (%) 87.1 27.1 68.6*** 44.1 89.4 
T2DM (%) 23.5 2.9 24.3*** 36.8   21.3 
Smoking 
    Active (%) 














  8.5 
  46.8 
BMI (kg/m2) 28.0±4.6 28.3±5.5 28.4±3.8 28.1±5.5   28.7±4.2 
      
Medication      
Antiplatelet (%) 73.1 15.7 90.0*** 18.0 87.4 
ACEi/ARBs (%) 62.3 21.4 77.1*** 36.1 60.0 
Statins (%) 78.2 22.9 68.6*** 41.0 89.5 
βblocker (%) 65.2 24.3 70.0*** 23.0 75.8 
CCB (%) 23.9 14.3 27.1 13.1 20.0 
Insulin (%) 13.3 0.0 10.0** 0.0 5.3 








Table S2. Demographic characteristics of study 1 participants per body mass index (BMI) 
group. BMI: Body mass index; T2DM: Type 2 diabetes mellitus; ACEi: Angiotensin 
converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CCB: Calcium channel 
blockers; +Mean±SD; BMI information missing from 40 of the patients in Study 1. *P < 0.05; 
**P < 0.01; ***P < 0.001 between the groups by Chi-Square tests 
BMI group 











Participants (n) 25 217 432 233 57 
+Age (years) 67.3±16.8 67.5±10.9 67.5±9.5 65.5±9.8 65.3±9.7 
Males (%) 64.0 83.9 82.2 78.5 78.9 
Hypertension (%)*** 58.3 61.8 70.1 76.4 89.3 
Hyperlipidaemia (%) 50.0 53.0 49.2 60.5 52.9 
T2DM (%)* 20 17.2 21.7 28.8 33.9 
Smoking 
    Active (%) 
















Medication      
Antiplatelet (%) 60.0/8.0 73.5/31.8 73.7/28.9 74.6/28.0 73.2/30.4 
ACEi/ARBs (%) 36.0/29.2 50.2/6.2 46.1/14.1 49.4/18.5 51.8/23.2 
Statins (%) 68.0 79.1 76.5 81.1 76.8 
βblocker (%)** 52.0 67.3 64.2 66.1 64.3 
CCB (%)* 16.0 18.0 22.8 30.0 30.4 
Insulin (%)** 5.0 2.5 5.0 9.0 14.3 
Oral hypoglycaemic (%)** 10.0 10.9 16.2 21.9 26.8 






Table S3. Multivariate linear regression models of calcified plaque progression and new-
onset calcification. Bstand: Standardised linear regression beta (β) coefficient. 
Calcified plaque progression 
Variable Bstand P 
Plasma WNT5A 0.242 0.047* 
Age (per decade of years) 0.191 0.115 
Male sex  0.144 0.234 
New onset calcification 
Variable Bstand P 
Plasma WNT5A 0.367 0.030* 
Age (per decade of years) – 0.069 0.666 














Table S4. Multivariate linear regression models of arterial NADPH-stimulated 
superoxide (O2.-) production. Bstand: Standardised beta (β) coefficient; PVAT: Perivascular 
adipose tissue; BMI: Body mass index. 
NADPH-stimulated O2.- 
Variable Bstand P 
PVAT WNT5A/SFRP5 ratio 0.362 0.039* 
BMI classification 0.316 0.069 
Diabetes 0.039 0.817 
Smoking -0.159 0.415 
Sex -0.086 0.650 
Age -0.025 0.885 
 
 
 
 
 
 
 
